On November 10, 2025, the U.S. Food and Drug Administration announced it was removing the long-standing “black box” warning from many menopausal hormone replacement therapy (HRT) labels. For many women, that warning created fear and confusion about whether hormones are “too risky,” even when facing unmanageable symptoms.Menopausal HRT involves taking estrogen, with or without a …

Continue reading “When Labels Change but Confusion Remains: Supporting Women Through HRT’s New Era”